Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ambien Not Sleepwalking Through Scrutiny; Label Warnings Updated

Executive Summary

Sanofi's sleeping pill has been revised once again in an update that also limits the recommended dosing.

You may also be interested in...



Gender-Based Dosing For Insomnia Drugs Dissected In NEJM

CDER officials explain the rationale behind new labeling on zolpidem-containing immediate- and controlled-release products that halves the recommended dose for women. Labeling changes include a new precaution against next-day driving following use of Sanofi’s Ambien CR.

Rep. Kennedy to join Ambien lawsuit?

Rep. Patrick Kennedy (D-R.I.) says he will check himself into the Mayo Clinic for rehab after he ran into a security barrier in Washington, D.C. May. When Capitol Police picked up the disoriented congressman at 2:45 a.m., he claimed he was headed to the Capitol for a vote. In a statement, Kennedy maintained that he was not under the influence of alcohol at the time of the incident, but admitted to having taken Sanofi-Aventis' insomnia therapy Ambien and Wyeth's antihistamine Phenergan. A recently filed class action lawsuit alleges Sanofi failed to adequately warn patients of risk of sleep walking and eating with Ambien (1"The Pink Sheet" March 20,2006, p. 18)...

Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data

After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.

Topics

Related Companies

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel